Sowell Financial Services’s Galectin Therapeutics GALT Stock Holding History

Sowell Financial Services’s Portfolio GALT Stock Details GALT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-5,515	Closed	-$20K	–	1355
2021 Q1	$20K	Hold	5,515	–	–	﹤0.01%	2057
2020 Q4	$12K	Hold	5,515	–	–	﹤0.01%	1942
2020 Q3	$15K	Hold	5,515	–	–	﹤0.01%	1673
2020 Q2	$17K	Hold	5,515	–	–	﹤0.01%	1514
2020 Q1	$11K	Hold	5,515	–	–	﹤0.01%	1577
2019 Q4	$16K	Hold	5,515	–	–	﹤0.01%	1510
2019 Q3	$20K	Buy	+5,515	New	+$19.9K	﹤0.01%	1275

Other funds holding GALT

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

GWM

Geneos Wealth Management Englewood, Colorado $4.9B AUM 23.65% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

CCB

Cutter & Co Brokerage Ballwin, Missouri $423M AUM 15.02% 1-Year Est. Return

Cambridge Investment Research Advisors Fairfield, Iowa $44.6B AUM 28.94% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Sowell Financial Services's GALT Position: Q2 2021 in Review

Sowell Financial Services sold out of Galectin Therapeutics (GALT) in Q2 2021, closing a stake of 5,515 shares — an estimated $20K sold.

Sowell Financial Services first reported a position in GALT in Q3 2019 and held it in 7 quarters. The position peaked at $20K in Q1 2021. 75 funds tracked by Wall St. Rank hold GALT as of Q2 2021.

Sowell Financial Services reported no remaining Galectin Therapeutics position as of Q2 2021 after selling out during the quarter.
Sowell Financial Services sold 5,515 Galectin Therapeutics shares in Q2 2021, an estimated $20K.
Sowell Financial Services first reported a position in Galectin Therapeutics in Q3 2019 and held it in 7 quarters.
Sowell Financial Services's Galectin Therapeutics position peaked at $20K in Q1 2021.
75 funds tracked by Wall St. Rank held Galectin Therapeutics as of Q2 2021.

Based on Sowell Financial Services's 13F filing for Q2 2021, filed 5 Aug 2021.